Abstract: An information processing apparatus includes a processor that: receives, from a user terminal, a request for first update regarding a first vehicle, notifies the user terminal that the first update is to be performed at a shop, when the first update is update of hardware, and notifies the user terminal that the first update is to be performed through wireless communication, when the first update is update of software.

Abstract: A power generation system includes: a prime mover; a magnetic gear generator configured to be driven by an input from the prime mover to generate power; a power converter connected to the magnetic gear generator; an operation mode switch unit configured to switch an operation mode of the magnetic gear generator to a step-out avoidance mode in response to that a step-out parameter indicating a risk of step-out of the magnetic gear generator exceeds a prescribed allowable range; and a reduction command unit configured to give the prime mover an input reduction command to reduce the input from the prime mover and configured to give the power converter a torque reduction command to reduce a generator torque of the magnetic gear generator, in the step-out avoidance mode.

Abstract: A bidirectional DC-DC converter includes a first circuit that is configured to process a first voltage being a DC voltage and that includes a first electronic component including a first switching element; a second circuit that is configured to process a second voltage or a third voltage, the second voltage being a DC voltage supplied to an electric vehicle, the third voltage being a DC voltage generated in an electric vehicle, and that includes a second electric component with a lower withstand voltage than the first electronic component, the second electric component including a second switching element; and a control circuit configured to control switching of at least one of the first switching element and the second switching element wherein the bidirectional DC-DC converter is configured to convert the first voltage into the second voltage or convert the third voltage into the first voltage.

Abstract: A technique is needed which can amplify NK cells in vitro and prepare optimum number of NK cells for the adoptive immunotherapy. A method for amplifying NK cells is provided which comprises steps of: preparing cell population which is comprised of NK cells, removing T cells from the cell population which is comprised of NK cells, and, after removal of T cells, cultivating the remaining cells in a medium supplemented with 2500 to 2831 IU/mL of IL-2. The method for amplifying NK cells of the present invention may comprise a step of removing hematopoietic progenitor cells from the cell population. The present invention provides a pharmaceutical composition for adoptive immunotherapy, comprising NK cells which are prepared by the amplifying method of the present invention.

Abstract: The object of the present invention is to develop a technique in which NK cells having a high cytotoxic activity can be prepared with high purity from hematopoietic precursor cells without using a serum or feeder cells of an animal. A method for expanding NK cells includes the steps of expanding hematopoietic precursor cells under a single culturing condition using a medium supplemented with IL-15, SCF, IL-7 and Flt3L, and differentially inducing the cells obtained in the expanding step into NK cells under a culturing condition using a medium supplemented with IL-2. A pharmaceutical composition contains the NK cells prepared by the method for expanding NK cells of the present invention. The pharmaceutical composition of the present invention is used for treating an infectious disease and/or a cancer.

Abstract: A technique is needed which can amplify NK cells in vitro and prepare optimum number of NK cells for the adoptive immunotherapy. A method for amplifying NK cells is provided which comprises steps of: preparing cell population which is comprised of NK cells, removing T cells from the cell population which is comprised of NK cells, and, after removal of T cells, cultivating the remaining cells in a medium supplemented with 2500 to 2831 IU/mL of IL-2. The method for amplifying NK cells of the present invention may comprise a step of removing hematopoietic progenitor cells from the cell population. The present invention provides a pharmaceutical composition for adoptive immunotherapy, comprising NK cells which are prepared by the amplifying method of the present invention.